An evaluation of the budget impact of a new 20% subcutaneous immunoglobulin (Ig20Gly) for the management of primary immunodeficiency diseases in Switzerland
Richard F Pollock,1 Lisa M Meckley2 1Ossian Health Economics and Communications GmbH, Health Economics and Outcomes Research, Basel, Switzerland; 2Shire Plc, Outcomes Research and Epidemiology, Cambridge, MA, USA Introduction: While most individual primary immunodeficiency diseases (PID) are rare, t...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2018-04-01
|
| Series: | ClinicoEconomics and Outcomes Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/an-evaluation-of-the-budget-impact-of-a-new-20-subcutaneous-immunoglob-peer-reviewed-article-CEOR |